Vitamin Shoppe Inc. (NYSE:VSI) shares dropped 6.3% during mid-day trading on Wednesday . The stock traded as low as $26.71 and last traded at $26.71, with a volume of 211,461 shares. The stock had previously closed at $28.51.

VSI has been the subject of a number of research analyst reports. Robert W. Baird reaffirmed a “hold” rating on shares of Vitamin Shoppe in a report on Monday, May 16th. Wedbush reaffirmed an “outperform” rating and issued a $39.00 target price on shares of Vitamin Shoppe in a report on Wednesday, August 3rd. Jefferies Group reaffirmed a “hold” rating and issued a $32.00 target price (up from $30.00) on shares of Vitamin Shoppe in a report on Friday, May 6th. Zacks Investment Research raised shares of Vitamin Shoppe from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Tuesday, May 24th. Finally, Goldman Sachs Group Inc. cut shares of Vitamin Shoppe to a “hold” rating in a report on Saturday, April 30th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company. Vitamin Shoppe presently has an average rating of “Hold” and an average target price of $32.82.

The stock has a market cap of $630.16 million and a PE ratio of 15.65. The stock has a 50 day moving average price of $29.65 and a 200 day moving average price of $29.71.

Vitamin Shoppe (NYSE:VSI) last posted its earnings results on Wednesday, August 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.59 by $0.04. During the same period last year, the firm earned $0.57 earnings per share. The business had revenue of $332.70 million for the quarter, compared to analysts’ expectations of $331.58 million. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. Equities research analysts forecast that Vitamin Shoppe Inc. will post $2.17 EPS for the current year.

In other news, Director Guillermo Marmol bought 1,000 shares of Vitamin Shoppe stock in a transaction on Tuesday, May 31st. The stock was purchased at an average cost of $30.23 per share, with a total value of $30,230.00. Following the purchase, the director now directly owns 1,470 shares of the company’s stock, valued at approximately $44,438.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

An institutional investor recently raised its position in Vitamin Shoppe stock. Rhumbline Advisers increased its position in Vitamin Shoppe Inc. (NYSE:VSI) by 4.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,118 shares of the company’s stock after buying an additional 1,855 shares during the period. Rhumbline Advisers owned about 0.16% of Vitamin Shoppe worth $1,475,000 at the end of the most recent quarter.

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, which includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats; direct, which sells its products directly to consumers through the Internet, primarily at, and manufacturing, which provides custom manufacturing and private labeling of vitamin, mineral and supplement (VMS) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.